Menu
Search
|

Menu

Close
X

Roche Holding AG ROG.S (Virt-X Level 1)

216.45 CHF
-- (--)
As of Jun 20
chart
Previous Close 216.45
Open --
Volume --
3m Avg Volume 1,903,811
Today’s High --
Today’s Low --
52 Week High 255.00
52 Week Low 206.35
Shares Outstanding (mil) 862.56
Market Capitalization (mil) 183,332.00
Forward P/E 21.56
Dividend (Yield %) 8.30 ( 3.83 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.38 Mean rating from 29 analysts

KEY STATS

Revenue (mm, CHF)
FY17
53,299
FY16
50,576
FY15
48,145
EPS (CHF)
FY17
10.037
FY16
11.132
FY15
10.281
*Note: Units in Millions of Swiss Francs
**Note: Units in Swiss Francs

KEY RATIOS

Price to Earnings (TTM)
vs sector
21.56
33.88
Price to Sales (TTM)
vs sector
3.44
8.30
Price to Book (MRQ)
vs sector
6.99
4.32
Price to Cash Flow (TTM)
vs sector
14.42
22.70
Total Debt to Equity (MRQ)
vs sector
71.71
17.35
LT Debt to Equity (MRQ)
vs sector
59.90
12.89
Return on Investment (TTM)
vs sector
17.02
13.21
Return on Equity (TTM)
vs sector
34.29
15.18

EXECUTIVE LEADERSHIP

Severin Schwan
Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director, Since 2013
Salary: CHF4,000,000.00
Bonus: CHF2,791,950.00
Christoph Franz
Non-Executive Chairman of the Board, Since 2011
Salary: CHF3,500,000.00
Bonus: CHF558,390.00
Fritz Gerber
Honorary Chairman of the Board, Since 2004
Salary: --
Bonus: --
Andre Hoffmann
Non-Executive Vice Chairman of the Board, Since
Salary: CHF400,000.00
Bonus: --
Alan Hippe
Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer, Since 2011
Salary: CHF1,600,000.00
Bonus: CHF2,000,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Grenzacherstr. 124
BASEL     4058

Phone: +419.732354295

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

SPONSORED STORIES